Placeholder Banner

BIO Comments on FDA Draft Guidance on Postapproval Pregnancy Safety Studies

July 1, 2019

BIO submitted comments on the Food and Drug Administration (FDA) Draft Guidance on Postapproval Pregnancy Safety Studies.

BIO expresses support for the goal of enhancing the medical community’s knowledge of the effects of medicines on pregnant women. In addition, BIO commends the FDA for welcoming the use of other types of post-approval studies other than pregnancy registries to monitor the safety of products during pregnancy.

BIO notes the majority of the guidance is focused on pregnancy registries, implying they are the default mechanism for conducting pregnancy surveillance after marketing. BIO urges FDA to consider amending the guidance and consider all possible limitations of pregnancy registries and all possible methods of pregnancy surveillance as well as the use of existing systems to collect and evaluate pregnancy information, such as pharmacovigilance studies.

Download Full Comments Below
BIO Letter Post Appoval Pregnacny Safety Study FDA-2018-D-4693
Read the full comments below
Discover More
We write as a coalition of advocates for the startup ecosystem to voice our strong support for the IGNITE American Innovation Act, legislation to support startups through the economic crisis by allowing companies to monetize tax assets generated…
The following letter provides BIO’s feedback on a number of regulatory proposals by the Centers for Medicare & Medicaid Services that would ease barriers to use of value-based purchasing arrangements within Medicaid and commercial plans, broaden…
The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments on the Draft Guidance for Industry “Interpreting Sameness of Gene Therapy Products Under the Orphan Drug…